Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding

Burden of Disease and Cost of Chronic Hepatitis C Virus Infection in Canada

(2016) Robert P Myers et al.   Canadian Journal of Gastroenterology and Hepatology

The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance

(2014) Udayan Chatterji et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity

(2014) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Targeting the NS5A protein of HCV: An emerging option

(2014) D.G. Cordek et al.   DRUGS OF THE FUTURE

Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication

(2014) Carola Berger et al.   GASTROENTEROLOGY

Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors

(2014) David R. McGivern et al.   GASTROENTEROLOGY

Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study

(2014) Hiromitsu Kumada et al.   HEPATOLOGY RESEARCH

Expanding the Proteome of an RNA Virus by Phosphorylation of an Intrinsically Disordered Viral Protein

(2014) Daniel G. Cordek et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes

(2014) Khaled H. Barakat et al.   Journal of Chemical Information and Modeling

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

(2014) Mark S. Sulkowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors

(2014) Sebastian M. Lambert et al.   PROTEIN SCIENCE

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

(2014) David B. Ascher et al.   Scientific Reports

Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance

(2014) Precious J Lim et al.   Current Opinion in Virology

A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity

(2014) Hangfei Qi et al.   PLoS Pathogens

Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

(2013) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity

(2013) Craig A. Coburn et al.   ChemMedChem

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

(2013) Gregory T. Everson et al.   GASTROENTEROLOGY

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterizations of HCV NS5A replication complex inhibitors

(2013) Donald R. O'Boyle II et al.   VIROLOGY

Profile of alisporivir and its potential in the treatment of hepatitis C

(2013) Philippe Gallay et al.   Drug Design Development and Therapy

The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A

(2013) Simon Reiss et al.   PLoS Pathogens

In VitroActivity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A

(2012) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Boceprevir

(2012) Karly P. Garnock-Jones   DRUGS

Telaprevir

(2012) Caroline M. Perry   DRUGS

Hepatitis C Virus NS5B and Host Cyclophilin A Share a Common Binding Site on NS5A

(2012) Claire Rosnoblet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling

(2012) Harel Dahari et al.   JOURNAL OF HEPATOLOGY

The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance

(2012) Matthias Götte   Current Opinion in Virology

In VitroActivity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A

(2011) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization

(2011) D. Qiu et al.   JOURNAL OF GENERAL VIROLOGY

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

(2011) R. A. Fridell et al.   JOURNAL OF VIROLOGY

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

(2011) M. H. Powdrill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IL28B polymorphisms and chronic hepatitis C

(2010) S. Chevaliez et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Recombinant HCV Variants With NS5A From Genotypes 1–7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α

(2010) Troels K.H. Scheel et al.   GASTROENTEROLOGY

Hepatitis C Virus Nonstructural Protein 5A: Biochemical Characterization of a Novel Structural Class of RNA-Binding Proteins

(2010) J. Hwang et al.   JOURNAL OF VIROLOGY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

The Domain 2 of the HCV NS5A Protein Is Intrinsically Unstructured

(2010) Xavier Hanoulle et al.   PROTEIN AND PEPTIDE LETTERS

Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded

(2009) Xavier Hanoulle et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of Hepatitis C Virus NS5A Inhibitors

(2009) J. A. Lemm et al.   JOURNAL OF VIROLOGY

Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus

(2009) R. A. Love et al.   JOURNAL OF VIROLOGY

Pegylated interferon-α-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study

(2009) Georges-Philippe Pageaux et al.   TRANSPLANT INTERNATIONAL

Hepatitis C virus infection protein network

(2008) B de Chassey et al.   Molecular Systems Biology